In: Finance
Following the outbreak of the Novel Coronavirus (COVID
19), CPC a pharmaceutical company is considering introducing a new
vaccine unto the market to help fight the virus. This will require
the injection of huge capital to the tune of GH¢40,000,000 for the
purchase of the equipment for production. It will cost CPC an
additional GH¢ 5,500,000 to set up the production facility and
install that equipment for production. Mr. Smart, the CEO of CPC
believes that the vaccine could be manufactured in a building owned
by the firm and located in East Legon. This vacant building and the
land can be sold for GH¢ 1,500,000 after taxes. CPC will finance
the production of the vaccine (including initial working capital
investment) by issuing 2000,000 new common stocks at GH¢ 20 per
share from its existing shareholders. A total of GH¢ 40,000,000 is
expected to be raised from the rights issue. It expects to finance
the remaining investment including initial working capital
investment from the issue of a 5-year bond with a before-tax yield
to maturity (YTM) of 12%. Mr. Qwesi, the Finance Director has
estimated the beta of the project to be 2.5 and the average return
for stocks traded on the Ghana Stock Exchange to be 10% while the
rate on Government of Ghana traded Treasury bills is 5%. The
successful production of the vaccine will generate additional cash
flows for CPC. The Production and Marketing department has
presented the information in the table below:
2020
Variable cost per unit of the product GH¢150
Selling price per unit GH¢350
Quantity 400,000units per annum
Again the following information should be taken note of:
• Feasibility studies cost the company GH¢2,000,000
• Test marketing expenses amounts to GH¢1,000,000
• The research into the discovery of the vaccine costs
GH¢5,000,000
• Variable cost will increase by 5% per annum
• Selling price will increase by 10% per annum
• Marketing expense will be 5% of sales revenue per year
• Overhead cost will be fixed at GH¢6000,000 per year
• The project will last for five (5) years (2021-2025)
• Charge depreciation using the straight-line method
• Salvage value for equipment is GH¢2,000,000
• CPC falls within the 25% tax bracket
• An initial working capital investment of GH¢10,000,000 will be
made. Subsequently, net working capital at the end of each year
will be equal to 10 percent of sales for that year. In the final
year of the project, net working capital will decline to zero as
the project is wound down. In other words, the investment in
working capital is to be completely recovered by the end of the
project’s life
• The introduction of this new vaccine is expected to lead to
10,000 units per annum drop in sales of vaccines for other types of
corona virus by. The selling price per unit of existing products is
GH¢100 while the variable cost is GH¢70. This has no tax
implications for the new vaccine.
• The project will be financed with debt and equity
Required:
a. Evaluate the project using the NPV and Profitability index and
recommend whether CPC should go ahead with the production of the
vaccine.